Page 133 - Genentech News Today

In this month's roundup of Bay Area Jewish community news: Camp Tawonga receives a Climate Action Fund grant; JCC Sonoma County and Peninsula Sinai get new professional leadership; and more.

One day, we may look back on 2023 as the year when it became apparent that the gigantic industry of raising animals for food was heading the same way as the industry that for most of the 20th century dominated how we record and store images. Is this year the equivalent, for animal production, of 1989, when the first digital camera aimed at the general public was launched? There are signs that it might be, starting wi...

/PRNewswire/ -- Westlake Village BioPartners ("Westlake") today announced the launch of its third fund of $450 million to incubate and grow early stage...

Lung cancer is the leading cancer killer of both men and women in the United States, however, people of color suffer disproportionally from lung cancer. According to the “State of Lung Cancer” report, the rate of new lung cancer cases is 76 per 100,000 population among Black Americans in Missouri, which is significantly higher than the rate of 59 among Black Americans nationally and significantly higher than the rate of 71 among whites in Missouri.

Berkeley Lab and Genentech are collaborating to make the next generation of lipid nanoparticles (LNPs) for drug delivery. Combining structural biology with cutting edge pharmaceutical science, the team is designing LNPs that can precisely deliver vaccines and therapeutics to target tissues while improving the product’s shelf life and duration of action.

The medical marketing industry’s biggest night of the year is scheduled for October 5 at Cipriani Wall Street.

The Hatch-Waxman Act established the U.S. Food and Drug Administration's approval and litigation process for generic drugs.

Many diseases can be successfully treated in the simple environment of a cell culture dish, but to successfully treat real people, the drug agent has to take a journey through the infinitely more complex environment within our bodies and arrive, intact, inside the affected cells.

This randomized clinical trial examines the efficacy and adverse effects of donanemab, a monoclonal antibody designed to clear brain amyloid plaque, among patie

​​​​​​​Yesterday, Genentech, Inc., Hoffmann-LaRoche, Inc., and Chugai Pharmaceutical Co., Ltd. (“Genentech”) filed BPCIA litigation against Biogen MA Inc. and Bio-Thera Solutions, Ltd....